Physician profile
James D Proffitt
NPI 1871542233
$3,804.80
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,709 · 2020: $1,260 · 2021: $835.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $582.78 | 2019-2021 | |
| Pfizer INC. | $425.46 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $349.45 | 2019-2020 | |
| Lilly USA, LLC | $333.78 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $278.20 | 2019-2021 | |
| Abbvie INC. | $203.95 | 2019-2021 | |
| Allergan, INC. | $174.17 | 2019-2020 | |
| Amarin Pharma, INC. | $165.21 | 2019-2021 | |
| Glaxosmithkline, LLC. | $137.33 | 2019-2021 | |
| Amgen INC. | $134.11 | 2019-2021 | |
| Zyla Life Sciences, INC. | $107.70 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $95.32 | 2019-2021 | |
| Antares Pharma, INC. | $86.92 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $81.16 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $80.81 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $76.74 | 2019-2021 | |
| Biocompatibles, INC. | $73.36 | 2019 | |
| Novartis Pharmaceuticals Corporation | $71.28 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $62.58 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $53.13 | 2019-2021 | |
| Eisai INC. | $45.73 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.63 | 2020-2021 | |
| Aytu Biopharma, INC. | $30.13 | 2019 | |
| Genentech USA, INC. | $20.32 | 2019 | |
| Clarus Therapeutics INC. | $20.07 | 2021 | |
| Esperion Therapeutics, INC. | $18.72 | 2021 | |
| Assertio Therapeutics, INC. | $17.47 | 2020 | |
| Medtronic Vascular, INC. | $11.94 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $11.79 | 2019 | |
| Currax Pharmaceuticals LLC | $11.56 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Proffitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.